Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems
2014 (English)In: Therapeutic delivery, ISSN 2041-5990, E-ISSN 2041-6008, Vol. 5, no 4, 447-466 p.Article in journal (Refereed) Published
The biopharmaceutical properties of doxorubicin delivered via two drug-delivery systems (DDSs) for the palliative treatment of unresectable hepatocellular carcinoma were reviewed with relation to the associated liver and tumor (patho)physiology. These two DDSs, doxorubicin emulsified with Lipiodol(®) and doxorubicin loaded into DC Bead(®) are different regarding tumor delivery, release rate, local bioavailability, if and how they can be given repeatedly, biodegradability, length of embolization and safety profile. There have been few direct head-to-head comparisons of these DDSs, and in-depth investigations into their in vitro and in vivo performance is warranted.
Place, publisher, year, edition, pages
2014. Vol. 5, no 4, 447-466 p.
IdentifiersURN: urn:nbn:se:uu:diva-246080DOI: 10.4155/tde.14.11PubMedID: 24856170OAI: oai:DiVA.org:uu-246080DiVA: diva2:791795